-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the...
IN THE SPOTLIGHT
-
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community. -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools...
Genetics-guided screening and biological validation identify zeylenol as a promising EGFR inhibitor in glioma
Genetics-guided screening and biological validation identify zeylenol as a promising EGFR inhibitor in glioma
Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation
Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the people who enroll in the trials need to represent the populations who are diagnosed in everyday life.Recognizing these needs, federal agencies like the United States Food and Drug Administration (FDA) have been encouraging clinical trials to offer more locations across the US.The PlanThe intention…
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR...
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR...
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System
Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System
Fused Imidazo[1,2-a]pyrimidines Containing 1,2,3-Triazoles and Isoxazoles: One-Pot Synthesis, Anticancer, and EGFR-Inhibitory Activities
Fused Imidazo[1,2-a]pyrimidines Containing 1,2,3-Triazoles and Isoxazoles: One-Pot Synthesis, Anticancer, and EGFR-Inhibitory Activities
Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories
Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories
ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma
Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer
Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer
Podcast: Why Community Matters in Lung Cancer Care
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to lung cancer to her own diagnosis, as well as her work building patient communities around the world. She discusses how connecting with others has shaped her journey and why community is important for support, information, and advocacy.Hosts Ann Steagall, RN, BSN, and Misty Shields, MD, PhD, explore with Jill how…
Podcast: Lung Cancer Diagnosis—What Happens Next
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from initial scans and biopsies through multiple treatments, and the moment a later biopsy revealed a biomarker that led to a targeted therapy.Hosts Ann Steagall and Misty Shields, MD, PhD, then speak with Anne Chiang, MD, PhD, thoracic oncologist at Yale University, about what patients can expect at their first visit,…
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who understand them and what they’re going through.Periodically, we invite an expert to speak on a topic at the beginning of a meetup, with the second half dedicated to questions and conversation. Visit the online calendar to see our virtual meetups and other upcoming events.For this meetup, we welcomed Jenna Doyle Ruhl and…
Meet The “Mini-Organs” of Lung Cancer Research
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their new puppy brings a smile. We interact with our environment every moment of the day. And so do lung cancer cells. A Brief HistoryTraditionally, we have studied tumor cells in isolation. We often study single cells in a petri dish, or under a microscope, to understand how they work. This has been very important and…
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted by the International Association for the Study of Lung Cancer, this annual gathering was held in Huntington Beach, California from Feb. 18-21, 2026. It has become known as one of the key meetings for participants to discuss the latest breakthroughs and challenges in lung cancer.This year’s meeting…
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
Biggest News from Berlin: Research Highlights from ESMO
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon…
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Veteran Voices: Surgery to Survivorship at the VA
Veteran Voices: Surgery to Survivorship at the VA
Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael. Michael is a veteran of the Vietnam War and uses the…
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine kinase inhibitors (TKIs), has brought real hope to people with EGFR-positive lung cancer—a lung cancer subtype driven by specific mutations in the EGFR gene. These drugs can shrink tumors dramatically, sometimes so much that they seem to disappear on scans. But beneath these promising results lies a stubborn problem: a small number of cancer…
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to optimize existing therapies and are exploring entirely new treatment approaches. At the 2025 World Conference on Lung Cancer (WCLC), several studies highlighted progress in treating newly diagnosed individuals as well as those who need new options after standard therapies stop working. Combining Chemotherapy and…
6 Tips for Managing Scanxiety
6 Tips for Managing Scanxiety
Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
New Treatment for Patients with Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
New Treatment for Patients with Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
On July 2, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sunvozertinib (Zegfrovy®) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins). These mutations are found in approximately 2% of patients with NSCLC. Sunvozertinib is a tyrosine kinase inhibitor (TKI) that targets EGFR exon20ins in patients whose tumors have started to grow again after chemotherapy.The FDA…
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
When a person is treated for advanced-stage lung cancer, tumors will often shrink, and their symptoms may subside. An effective treatment will kill many tumor cells, but there are usually some cells (called drug-tolerant persister cells, or DTPCs) left behind. If these cancer cells survive treatment, they will eventually begin to grow again.Researchers have been making progress in understanding how DTPCs grow and, importantly, how that growth can be stopped. As we learn more about these cells,…